LifeMD (NASDAQ:LFMD) Price Target Raised to $15.00

LifeMD (NASDAQ:LFMD) had its price objective increased by research analysts at Cantor Fitzgerald from $13.00 to $15.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 57.07% from the stock’s previous close.

A number of other research analysts have also recently weighed in on LFMD. HC Wainwright lifted their price objective on LifeMD from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, January 11th. BTIG Research upped their price target on shares of LifeMD from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.60.

LifeMD Stock Performance

NASDAQ:LFMD traded down $2.78 on Thursday, hitting $9.55. The stock had a trading volume of 1,929,867 shares, compared to its average volume of 819,536. The business’s 50-day simple moving average is $10.18 and its two-hundred day simple moving average is $8.08. The stock has a market cap of $390.50 million, a price-to-earnings ratio of -13.89 and a beta of 1.38. LifeMD has a 52-week low of $1.66 and a 52-week high of $12.88. The company has a quick ratio of 1.15, a current ratio of 1.22 and a debt-to-equity ratio of 3.22.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Monday, March 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The business had revenue of $44.86 million for the quarter, compared to the consensus estimate of $40.65 million. As a group, research analysts predict that LifeMD will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in LFMD. Tower Research Capital LLC TRC boosted its stake in LifeMD by 266.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $38,000 after buying an additional 3,348 shares during the last quarter. Dorsey Wright & Associates bought a new position in shares of LifeMD during the 3rd quarter valued at approximately $37,000. Worth Venture Partners LLC purchased a new position in shares of LifeMD in the third quarter valued at $64,000. Freedom Wealth Alliance LLC bought a new stake in LifeMD in the third quarter worth $68,000. Finally, Thompson Davis & CO. Inc. purchased a new stake in LifeMD during the fourth quarter valued at $117,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.